Eczema creams and pregnancy outcomes study
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at women who used a topical eczema cream called ruxolitinib (Opzelura) or steroid creams during pregnancy. The goal is to compare pregnancy outcomes and baby health up to one year after birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 14 or older when the pregnancy ended.
- Your pregnancy happened after September 21, 2021.
- You used either ruxolitinib cream (Opzelura) or strong steroid creams for eczema during pregnancy.
- You had eczema diagnosed before or on the day you first got the cream or steroid.
- You have continuous health coverage from 6 months before your pregnancy started through the end of pregnancy.
- You did NOT take oral ruxolitinib or other JAK inhibitor pills during pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
This trial tests a cream called Opzelura (ruxolitinib) for people with mild-to-moderate eczema on at least two body areas. It aims to see how well the cream works in everyday use for people ages 2 and older.
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
This study tracks the safety of abrocitinib (CIBINQO) during pregnancy and what it may mean for the baby. You may join if you were pregnant recently or are currently pregnant and have taken CIBINQO, or if you have moderate-to-severe atopic dermatitis.
This is an observational study that looks back at medical and pharmacy records of women with atopic dermatitis around pregnancy. It may help researchers better understand how this condition affects pregnant patients and pregnancy-related care.
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hear when a new Pregnancy Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.